Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Cardiotoxicity 6Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Neuroblastoma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Ganglioneuroblastoma 2Burkitt Lymphoma 2Blast Crisis 2Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Osteosarcoma 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Doxorubicin 17Ifosfamide 12Radiotherapy 8pazopanib 5selinexor 4pembrolizumab 4Filgrastim 4pegfilgrastim 3Sirolimus 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Etoposide 3AZD 6244 3fludarabine phosphate 2brostallicin 2X-Rays 2Trabectedin 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Radiation 2Diathermy 2Chemotherapy, Adjuvant 2Biopsy 2thymoglobulin 1temsirolimus 1tazemetostat 1sotigalimab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibrosarcoma × Razoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡